IO Biotech Statistics
Total Valuation
IO Biotech has a market cap or net worth of $49.52 million. The enterprise value is $36.97 million.
Important Dates
The last earnings date was Friday, November 14, 2025, before market open.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IO Biotech has 65.88 million shares outstanding. The number of shares has increased by 0.31% in one year.
| Current Share Class | 65.88M |
| Shares Outstanding | 65.88M |
| Shares Change (YoY) | +0.31% |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 5.62% |
| Owned by Institutions (%) | 15.02% |
| Float | 37.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 57.50 |
| P/TBV Ratio | 54.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01, with a Debt / Equity ratio of 19.89.
| Current Ratio | 2.01 |
| Quick Ratio | 1.67 |
| Debt / Equity | 19.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -80.82 |
Financial Efficiency
Return on equity (ROE) is -240.48% and return on invested capital (ROIC) is -122.91%.
| Return on Equity (ROE) | -240.48% |
| Return on Assets (ROA) | -88.58% |
| Return on Invested Capital (ROIC) | -122.91% |
| Return on Capital Employed (ROCE) | -425.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.10M |
| Employee Count | 80 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -955,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.05% in the last 52 weeks. The beta is 0.46, so IO Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | -14.05% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 44.21 |
| Average Volume (20 Days) | 1,278,774 |
Short Selling Information
The latest short interest is 2.76 million, so 4.19% of the outstanding shares have been sold short.
| Short Interest | 2.76M |
| Short Previous Month | 1.14M |
| Short % of Shares Out | 4.19% |
| Short % of Float | 7.40% |
| Short Ratio (days to cover) | 0.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -92.05M |
| Pretax Income | -89.30M |
| Net Income | -88.35M |
| EBITDA | -91.80M |
| EBIT | -92.05M |
| Earnings Per Share (EPS) | -$1.34 |
Full Income Statement Balance Sheet
The company has $30.66 million in cash and $18.12 million in debt, giving a net cash position of $12.55 million or $0.19 per share.
| Cash & Cash Equivalents | 30.66M |
| Total Debt | 18.12M |
| Net Cash | 12.55M |
| Net Cash Per Share | $0.19 |
| Equity (Book Value) | 911,000 |
| Book Value Per Share | 0.01 |
| Working Capital | 18.52M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$81.00 million and capital expenditures -$69,000, giving a free cash flow of -$81.07 million.
| Operating Cash Flow | -81.00M |
| Capital Expenditures | -69,000 |
| Free Cash Flow | -81.07M |
| FCF Per Share | -$1.23 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IO Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.31% |
| Shareholder Yield | -0.31% |
| Earnings Yield | -178.42% |
| FCF Yield | -163.71% |
Analyst Forecast
The average price target for IO Biotech is $3.50, which is 365.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.50 |
| Price Target Difference | 365.67% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |